$8.77
0.192.21%
At Close: -
$8.77
00.00%
After Hours: Jul 5, 4:00 PM EDT
15 minutes delayed
Enfusion
ENFNNYSE
Enfusion (NYSE:ENFN) Stock, Analyst Ratings, Price Targets, Forecasts
Enfusion Inc has a consensus price target of $9.9 based on the ratings of 33 analysis. The 3 most-recent analyst ratings were released by B of A Securities, Goldman Sachs, and JP Morgan on March 13, 2024, February 28, 2024, and January 30, 2024, respectively. With an average price target of $8.67 between B of A Securities, Goldman Sachs, and JP Morgan, there's an implied -1.18% downside for Enfusion Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
Goldman Sachs
JP Morgan
Piper Sandler
UBS
1calculated from analyst ratings
Analyst Ratings for Enfusion
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/13/2024 | Buy Now | 2.62% | B of A Securities | Koji Ikeda | $8 → $9 | Maintains | Underperform | Get Alert |
| 02/28/2024 | Buy Now | -8.78% | Goldman Sachs | Gabriela Borges | $9 → $8 | Downgrade | Neutral → Sell | Get Alert |
| 01/30/2024 | Buy Now | 2.62% | JP Morgan | Alexei Gogolev | $11 → $9 | Downgrade | Neutral → Underweight | Get Alert |
| 12/20/2023 | Buy Now | 14.03% | Piper Sandler | Sumeet Mody | $9 → $10 | Maintains | Neutral | Get Alert |
| 11/07/2023 | Buy Now | 2.62% | UBS | Kevin Mcveigh | → $9 | Initiates | → Neutral | Get Alert |
| 08/09/2023 | Buy Now | 14.03% | Goldman Sachs | Gabriela Borges | $11.5 → $10 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | 25.43% | Morgan Stanley | James Faucette | $12 → $11 | Maintains | Overweight | Get Alert |
| 05/22/2023 | Buy Now | 2.62% | Piper Sandler | Sumeet Mody | $11 → $9 | Maintains | Neutral | Get Alert |
| 05/10/2023 | Buy Now | 25.43% | Credit Suisse | Kevin Mcveigh | $14 → $11 | Maintains | Neutral | Get Alert |
| 04/03/2023 | Buy Now | 25.43% | Piper Sandler | Sumeet Mody | → $11 | Initiates | → Neutral | Get Alert |
| 03/15/2023 | Buy Now | 36.83% | JP Morgan | Alexei Gogolev | → $12 | Initiates | → Neutral | Get Alert |
| 01/26/2023 | Buy Now | 8.32% | Goldman Sachs | Gabriela Borges | $14 → $9.5 | Maintains | Neutral | Get Alert |
| 01/04/2023 | Buy Now | 14.03% | B of A Securities | Koji Ikeda | $15 → $10 | Downgrade | Neutral → Underperform | Get Alert |
| 01/03/2023 | Buy Now | 36.83% | Morgan Stanley | James Faucette | $13 → $12 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/03/2022 | Buy Now | 71.04% | B of A Securities | Koji Ikeda | $17 → $15 | Downgrade | Buy → Neutral | Get Alert |
| 08/10/2022 | Buy Now | 48.23% | Morgan Stanley | James Faucette | $8 → $13 | Maintains | Equal-Weight | Get Alert |
| 07/14/2022 | Buy Now | 36.83% | Goldman Sachs | Gabriela Borges | $14 → $12 | Maintains | Neutral | Get Alert |
| 07/06/2022 | Buy Now | 36.83% | Piper Sandler | Christopher Donat | $15 → $12 | Maintains | Overweight | Get Alert |
| 05/13/2022 | Buy Now | -8.78% | Morgan Stanley | James Faucette | $18 → $8 | Maintains | Equal-Weight | Get Alert |
| 05/13/2022 | Buy Now | 82.44% | Credit Suisse | Kevin Mcveigh | $20 → $16 | Maintains | Neutral | Get Alert |
| 03/25/2022 | Buy Now | 105.25% | Morgan Stanley | James Faucette | $22 → $18 | Maintains | Equal-Weight | Get Alert |
| 03/25/2022 | Buy Now | 128.05% | Credit Suisse | Kevin Mcveigh | $25 → $20 | Maintains | Neutral | Get Alert |
| 03/21/2022 | Buy Now | 128.05% | Stifel | Parker Lane | $27 → $20 | Maintains | Buy | Get Alert |
| 03/16/2022 | Buy Now | 71.04% | Goldman Sachs | Gabriela Borges | $24 → $15 | Maintains | Neutral | Get Alert |
| 12/03/2021 | Buy Now | 150.86% | Morgan Stanley | James Faucette | — | Maintains | Equal-Weight | Get Alert |
| 12/03/2021 | Buy Now | 185.06% | Credit Suisse | Kevin Mcveigh | — | Maintains | Neutral | Get Alert |
| 11/16/2021 | Buy Now | — | William Blair | Bhavan Suri | — | Initiates | → Outperform | Get Alert |
| 11/15/2021 | Buy Now | 207.87% | Stifel | Parker Lane | — | Initiates | → Buy | Get Alert |
| 11/15/2021 | Buy Now | 242.08% | B of A Securities | Koji Ikeda | — | Initiates | → Buy | Get Alert |
| 11/15/2021 | Buy Now | 173.66% | Morgan Stanley | James Faucette | — | Initiates | → Equal-Weight | Get Alert |
| 11/15/2021 | Buy Now | 196.47% | Credit Suisse | Kevin Mcveigh | — | Initiates | → Neutral | Get Alert |
| 11/15/2021 | Buy Now | 196.47% | Goldman Sachs | Gabriela Borges | — | Initiates | → Neutral | Get Alert |
| 11/15/2021 | Buy Now | 196.47% | Piper Sandler | Christopher Donat | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Enfusion (ENFN) stock?
The latest price target for Enfusion (NYSE:ENFN) was reported by B of A Securities on March 13, 2024. The analyst firm set a price target for $9.00 expecting ENFN to rise to within 12 months (a possible 2.62% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Enfusion (ENFN)?
The latest analyst rating for Enfusion (NYSE:ENFN) was provided by B of A Securities, and Enfusion maintained their underperform rating.
When was the last upgrade for Enfusion (ENFN)?
The last upgrade for Enfusion Inc happened on January 3, 2023 when Morgan Stanley raised their price target to $12. Morgan Stanley previously had an equal-weight for Enfusion Inc.
When was the last downgrade for Enfusion (ENFN)?
The last downgrade for Enfusion Inc happened on February 28, 2024 when Goldman Sachs changed their price target from $9 to $8 for Enfusion Inc.
When is the next analyst rating going to be posted or updated for Enfusion (ENFN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enfusion, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enfusion was filed on March 13, 2024 so you should expect the next rating to be made available sometime around March 13, 2025.
Is the Analyst Rating Enfusion (ENFN) correct?
While ratings are subjective and will change, the latest Enfusion (ENFN) rating was a maintained with a price target of $8.00 to $9.00. The current price Enfusion (ENFN) is trading at is $8.77, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.